false--12-310001783183Q3http://fasb.org/srt/2025#ChiefExecutiveOfficerMember110001783183us-gaap:CommonStockMember2025-09-300001783183phat:LoanAgreementMember2023-12-140001783183phat:LoanAgreementMemberphat:TermLoansAggregatePrincipalAmountTranchesOneMember2021-09-170001783183phat:LoanAgreementMemberus-gaap:CommonStockMember2023-12-140001783183us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-310001783183us-gaap:SellingGeneralAndAdministrativeExpensesMember2025-01-012025-09-300001783183phat:UnvestedSharesMember2024-07-012024-09-300001783183us-gaap:ResearchAndDevelopmentExpenseMember2025-07-012025-09-300001783183phat:TwoThousandNineteenEquityIncentivePlanMember2019-01-012019-12-310001783183phat:OfficersOrDirectorsMember2025-07-012025-09-300001783183phat:EmployeeStockPurchasePlanMember2024-07-012024-09-300001783183us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310001783183us-gaap:EmployeeSeveranceMember2025-05-012025-05-310001783183us-gaap:RetainedEarningsMember2025-07-012025-09-300001783183phat:TakedaLicenseAgreementMember2025-07-012025-09-300001783183phat:UnvestedSharesMember2024-01-012024-09-3000017831832024-12-310001783183phat:LoanAgreementMemberphat:TermLoanSecondAdvanceMember2025-09-300001783183us-gaap:CommonStockMemberphat:IPOAndATMOfferingsMember2025-09-300001783183phat:ATMOfferingProgramMember2025-01-012025-09-300001783183phat:TwoThousandNineteenIncentiveAwardPlanMember2025-01-010001783183phat:LoanAgreementMemberphat:TermLoanMemberphat:PaymentInKindPikInterestRateMembersrt:MinimumMember2023-12-140001783183us-gaap:OverAllotmentOptionMember2024-08-202024-08-200001783183us-gaap:OverAllotmentOptionMember2025-01-012025-09-300001783183phat:LoanAgreementMemberphat:TermLoansAggregatePrincipalFundedAmountTranchesTwoMember2023-12-140001783183phat:LoanAgreementMemberphat:TermLoanAdvancePrepaymentPriorToOctoberOneTwoThousandTwentySixMember2023-12-142023-12-140001783183phat:TakedaPharmaceuticalCompanyLimitedMemberphat:TakedaLicenseAgreementMember2019-05-070001783183phat:TakedaLicenseAgreementMember2024-07-012024-09-300001783183us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-01-012024-09-300001783183us-gaap:SalesRevenueProductLineMember2025-01-012025-09-300001783183phat:LoanAgreementMemberphat:TermLoanAdvancePrepaymentPriorToOctoberOneTwoThousandTwentySixMembersrt:MaximumMember2023-12-142023-12-140001783183phat:ThreeCustomersMembersrt:MinimumMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-12-310001783183phat:LoanAgreementMemberphat:TermLoanAdvanceMember2025-09-300001783183phat:TwoThousandNineteenIncentiveAwardPlanMemberphat:StockOptionsPerformanceStockUnitsAndRestrictedStockUnitsMember2025-01-012025-09-300001783183phat:VoqueznaProductMember2024-01-012024-09-300001783183phat:LoanAgreementMemberphat:TermLoanMember2023-12-142023-12-140001783183phat:InitialInvestorsNqSagardAndHerculesMemberphat:RevenueInterestFinancingAgreementMember2022-05-030001783183phat:AmendmentToLoanAgreementMember2023-05-092023-05-090001783183phat:EmployeeStockPurchasePlanMember2025-01-012025-09-300001783183us-gaap:AccountsReceivableMember2025-01-012025-09-300001783183phat:AnneMarieCookMember2025-07-012025-09-300001783183phat:ThreeCustomersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueProductLineMember2025-07-012025-09-300001783183us-gaap:RetainedEarningsMember2024-06-300001783183us-gaap:FairValueMeasurementsRecurringMember2025-09-300001783183phat:UnvestedSharesMember2025-01-012025-09-300001783183us-gaap:SalesRevenueProductLineMember2025-07-012025-09-300001783183us-gaap:AdditionalPaidInCapitalMember2023-12-310001783183us-gaap:RetainedEarningsMember2024-07-012024-09-300001783183phat:TwoThousandTwentyFiveEmploymentInducementIncentiveAwardPlanMember2025-03-302025-03-3000017831832025-07-012025-09-300001783183us-gaap:RetainedEarningsMember2023-12-310001783183phat:ThreeCustomersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueProductLineMember2025-01-012025-09-3000017831832024-07-012024-09-300001783183us-gaap:CommonStockMember2025-07-012025-09-300001783183srt:MinimumMember2025-09-3000017831832024-09-300001783183phat:TwoThousandNineteenEquityIncentivePlanMember2019-10-310001783183phat:ThreeCustomersMemberus-gaap:CustomerConcentrationRiskMembersrt:MaximumMemberus-gaap:SalesRevenueProductLineMember2025-01-012025-09-300001783183phat:TakedaPharmaceuticalCompanyLimitedMemberphat:TakedaLicenseAgreementMember2019-05-072019-05-070001783183phat:ThreeCustomersMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2025-01-012025-09-300001783183phat:ATMOfferingProgramMember2024-01-012024-09-300001783183phat:TermLoanMemberphat:LoanAgreementMemberus-gaap:PrimeRateMember2023-12-142023-12-1400017831832025-06-300001783183phat:SteveBastMember2025-07-012025-09-300001783183us-gaap:AdditionalPaidInCapitalMember2025-06-300001783183phat:TwoThousandTwentyThreeAtmOfferingProgramMember2025-01-012025-09-300001783183phat:ThreeCustomersMembersrt:MinimumMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueProductLineMember2024-07-012024-09-300001783183us-gaap:CommonStockMember2024-03-310001783183us-gaap:RetainedEarningsMember2024-09-300001783183us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-09-300001783183us-gaap:PerformanceSharesMember2025-09-300001783183us-gaap:CommonStockMember2025-06-3000017831832025-01-012025-09-300001783183phat:RobertBreedloveMember2025-07-012025-09-300001783183phat:TakedaLicenseAgreementMember2024-01-012024-09-300001783183phat:StockOptionsPerformanceStockUnitsAndRestrictedStockUnitsMember2025-09-300001783183us-gaap:CommonStockMemberphat:EmployeeStockPurchasePlanMember2019-10-310001783183us-gaap:AdditionalPaidInCapitalMember2025-04-012025-06-300001783183phat:LoanAgreementMemberphat:TermLoansAggregatePrincipalAmountTranchesFiveMember2023-12-140001783183srt:MinimumMemberphat:RevenueInterestFinancingAgreementPercentageOnInvestmentAmountOnDecemberThirtyOneTwoThousandAndThirtySevenMember2022-05-0300017831832024-01-012024-12-310001783183phat:TermLoanFourAdvanceMemberphat:LoanAgreementMember2025-09-300001783183us-gaap:PerformanceSharesMember2025-01-012025-09-300001783183phat:RevenueInterestFinancingAgreementUponOccurrenceOfEventOfDefaultPriorToAprilOneTwoThousandAndTwentyFiveMember2022-05-030001783183us-gaap:CommonStockMember2024-07-012024-09-300001783183phat:ThreeCustomersMembersrt:MinimumMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueProductLineMember2025-07-012025-09-300001783183phat:LoanAgreementMemberphat:TermLoanMember2023-12-140001783183phat:CustomerCreditsDiscountsAndAllowanceMember2025-01-012025-09-300001783183us-gaap:CommonStockMember2024-12-310001783183us-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMember2025-01-012025-09-300001783183phat:CustomerCreditsDiscountsAndAllowanceMember2024-12-310001783183us-gaap:RetainedEarningsMember2025-01-012025-03-310001783183phat:LoanAgreementMemberphat:TermLoansAggregatePrincipalAmountTranchesFourMember2024-12-150001783183phat:ThreeCustomersMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-12-310001783183phat:RevenueInterestFinancingAgreementMember2022-05-032022-05-030001783183phat:TakedaPharmaceuticalCompanyLimitedMemberphat:TakedaLicenseAgreementMember2025-01-012025-09-300001783183stpr:NJ2025-09-300001783183phat:EmployeeStockPurchasePlanMember2025-01-010001783183phat:ATMOfferingProgramMember2025-07-012025-09-300001783183phat:RevenueInterestFinancingAgreementPercentageOnInvestmentAmountOnDecemberThirtyOneTwoThousandAndTwentyEightMembersrt:MinimumMember2022-05-030001783183phat:TwoThousandNineteenEquityIncentivePlanMember2019-12-310001783183us-gaap:RetainedEarningsMember2024-01-012024-03-310001783183phat:ThreeCustomersMemberus-gaap:CustomerConcentrationRiskMembersrt:MaximumMemberus-gaap:SalesRevenueProductLineMember2024-01-012024-09-300001783183phat:ThreeCustomersMemberus-gaap:CustomerConcentrationRiskMembersrt:MaximumMemberus-gaap:SalesRevenueProductLineMember2025-07-012025-09-300001783183us-gaap:CommonStockMemberphat:IPOAndATMOfferingsMember2025-01-012025-09-3000017831832024-06-300001783183us-gaap:CommonStockMember2024-01-012024-03-310001783183phat:RebatesReturnsAndCo-PayAssistanceMember2025-01-012025-09-300001783183us-gaap:FairValueMeasurementsNonrecurringMember2025-09-300001783183us-gaap:PerformanceSharesMember2024-12-310001783183phat:ThreeCustomersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueProductLineMember2024-07-012024-09-300001783183phat:ThreeCustomersMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMembersrt:MaximumMember2025-01-012025-09-300001783183us-gaap:CommonStockMember2024-09-3000017831832025-10-270001783183us-gaap:BaseRateMemberphat:TermLoanMemberphat:LoanAgreementMember2023-12-142023-12-140001783183phat:TwoThousandNineteenIncentiveAwardPlanMember2019-10-012019-10-310001783183us-gaap:EmployeeSeveranceMember2025-01-012025-09-300001783183phat:EmployeeStockPurchasePlanMember2025-09-300001783183phat:ThreeCustomersMemberus-gaap:CustomerConcentrationRiskMembersrt:MaximumMemberus-gaap:SalesRevenueProductLineMember2024-07-012024-09-300001783183phat:LoanAgreementMemberphat:TermLoansAggregatePrincipalFundedAmountTranchesTwoMember2024-03-1500017831832023-12-3100017831832024-03-310001783183us-gaap:AdditionalPaidInCapitalMember2025-03-310001783183phat:StockOptionsPerformanceStockUnitsAndRestrictedStockUnitsMemberphat:TwoThousandTwentyFiveEmploymentInducementIncentiveAwardPlanMember2025-01-012025-09-300001783183us-gaap:RetainedEarningsMember2024-04-012024-06-300001783183us-gaap:RestrictedStockMemberphat:TwoThousandNineteenEquityIncentivePlanMember2019-01-012019-12-310001783183phat:ShareBasedPaymentArrangementEmployeeAndNonemployeeMember2025-01-012025-09-300001783183us-gaap:CommonStockMemberus-gaap:OverAllotmentOptionMember2024-08-202024-08-200001783183phat:InitialInvestorsAndCoFinanceLVSXXXVIILLCAndHerculesMemberphat:JoinderAgreementAdditionalFundingUponFdaApprovalOrDuringTheFourthQuarterOfTwoThousandTwentyAndThreeMember2022-10-312022-10-310001783183phat:InitialInvestorsNqSagardAndHerculesMemberphat:RevenueInterestFinancingAgreementMembersrt:MaximumMember2022-05-032022-05-030001783183phat:InitialInvestorsNqSagardAndHerculesMemberphat:RevenueInterestFinancingAgreementFundingCommitmentOnDuringTheFourthQuarterOfTwoThousandTwentyAndThreeMember2023-11-282023-11-280001783183phat:UnvestedSharesMember2025-07-012025-09-300001783183phat:TermLoanMemberphat:LoanAgreementMemberphat:PaymentInKindPikInterestRateMembersrt:MaximumMember2023-12-140001783183phat:HerculesLoanAgreementMember2024-07-012024-09-300001783183us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-07-012024-09-300001783183us-gaap:RetainedEarningsMember2024-03-310001783183us-gaap:RetainedEarningsMember2025-06-300001783183phat:LoanAgreementMemberphat:TermLoanMembersrt:MaximumMemberus-gaap:PrimeRateMember2023-12-142023-12-140001783183us-gaap:RetainedEarningsMember2024-12-310001783183us-gaap:RetainedEarningsMember2025-04-012025-06-300001783183phat:RevenueInterestFinancingAgreementUponOccurrenceOfEventOfDefaultAfterAprilOneTwoThousandAndTwentyEightMember2022-05-030001783183phat:HerculesTermLoanMember2025-09-300001783183phat:HerculesLoanAgreementMember2025-01-012025-09-300001783183us-gaap:EmployeeStockOptionMember2025-01-012025-09-300001783183phat:LoanAgreementMemberphat:TermLoansAggregatePrincipalAmountTranchesThreeAndFourMember2021-09-170001783183phat:HerculesLoanAgreementMember2025-07-012025-09-300001783183us-gaap:CommonStockMember2025-01-012025-03-310001783183us-gaap:CommonStockMember2025-03-310001783183us-gaap:AdditionalPaidInCapitalMember2025-09-300001783183us-gaap:RestrictedStockUnitsRSUMember2024-12-3100017831832025-03-310001783183us-gaap:OverAllotmentOptionMemberus-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300001783183us-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMember2024-01-012024-09-300001783183phat:PriorToThreeMonthsTrailingMemberphat:LoanAgreementMember2023-12-142023-12-140001783183phat:TwoThousandTwentyFiveEmploymentInducementIncentiveAwardPlanMember2025-09-300001783183phat:CustomerCreditsDiscountsAndAllowanceMember2025-09-300001783183phat:TermLoanMemberphat:LoanAgreementMemberphat:PaymentInKindPikInterestRateMember2023-12-142023-12-140001783183phat:TwoThousandNineteenIncentiveAwardPlanMember2025-01-012025-09-300001783183us-gaap:CommonStockMember2025-04-012025-06-3000017831832025-01-012025-03-310001783183phat:LoanAgreementMembersrt:MaximumMemberphat:TermLoansAggregatePrincipalAmountTranchesSixMember2023-12-142023-12-1400017831832024-01-012024-09-300001783183phat:ThreeMonthsTrailingMember2025-01-012025-09-300001783183us-gaap:CommonStockMember2023-12-310001783183phat:InitialInvestorsAndCoFinanceLVSXXXVIILLCAndHerculesMemberphat:RevenueInterestFinancingAgreementMember2025-09-300001783183phat:ThreeMonthsTrailingMember2023-12-142023-12-140001783183phat:EmployeeStockPurchasePlanMember2019-10-012019-10-310001783183phat:EmployeeStockPurchasePlanMember2024-01-012024-09-300001783183phat:TermLoanMemberphat:LoanAgreementMembersrt:MinimumMember2023-12-140001783183phat:EmployeeStockPurchasePlanMember2025-07-012025-09-300001783183us-gaap:RestrictedStockUnitsRSUMember2025-09-300001783183us-gaap:CommonStockMember2024-06-300001783183us-gaap:CommonStockMemberus-gaap:OverAllotmentOptionMember2024-07-012024-09-300001783183phat:ThreeCustomersMembersrt:MinimumMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueProductLineMember2025-01-012025-09-300001783183us-gaap:CommonStockMember2024-04-012024-06-300001783183phat:LoanAgreementMemberphat:TermLoansAggregatePrincipalAmountTranchesSixMember2023-12-140001783183us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300001783183phat:RebatesReturnsAndCo-PayAssistanceMember2025-09-300001783183phat:HerculesLoanAgreementMember2024-01-012024-09-300001783183us-gaap:CommonStockMemberphat:TwoThousandNineteenIncentiveAwardPlanMember2019-10-012019-10-310001783183us-gaap:AdditionalPaidInCapitalMember2024-12-310001783183phat:TwoThousandTwentyThreeAtmOfferingProgramMembersrt:MaximumMemberphat:OpenMarketSaleAgreementWithJefferiesLLCMember2023-11-092023-11-090001783183phat:LoanAgreementMemberphat:TermLoanMember2021-09-170001783183phat:ThreeCustomersMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMembersrt:MaximumMember2024-01-012024-12-310001783183phat:AmendmentToLoanAgreementMember2022-09-270001783183phat:RevenueInterestFinancingAgreementMember2022-05-030001783183phat:ATMOfferingProgramMember2024-07-012024-09-300001783183us-gaap:SalesRevenueProductLineMember2024-01-012024-09-300001783183us-gaap:OverAllotmentOptionMember2024-08-200001783183phat:CommonStockWarrantMember2025-09-300001783183us-gaap:BaseRateMemberphat:LoanAgreementMemberphat:TermLoanMember2023-12-140001783183phat:RevenueInterestFinancingAgreementUponOccurrenceOfEventOfDefaultBetweenAprilOneTwoThousandAndTwentyFiveAndAprilOneTwoThousandAndTwentyEightMember2022-05-030001783183us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300001783183us-gaap:SalesRevenueProductLineMember2024-07-012024-09-300001783183us-gaap:ResearchAndDevelopmentExpenseMember2025-01-012025-09-300001783183phat:LoanAgreementMemberphat:TermLoanAdvanceMember2023-12-142023-12-140001783183us-gaap:AdditionalPaidInCapitalMember2024-09-300001783183phat:LoanAgreementMembersrt:MinimumMemberphat:TermLoansAggregatePrincipalAmountTranchesSixMember2023-12-142023-12-140001783183stpr:IL2025-09-300001783183phat:TakedaLicenseAgreementMember2025-09-300001783183phat:TermLoanMemberphat:LoanAgreementMember2021-09-172021-09-170001783183phat:LoanAgreementMemberphat:TermLoanThirdAdvanceMember2025-09-300001783183us-gaap:AdditionalPaidInCapitalMember2024-06-300001783183phat:TakedaLicenseAgreementMember2025-01-012025-09-300001783183phat:ThreeCustomersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueProductLineMember2024-01-012024-09-300001783183us-gaap:AdditionalPaidInCapitalMember2025-07-012025-09-300001783183phat:LoanAgreementMember2023-12-142023-12-140001783183phat:LoanAgreementMemberphat:TermLoanMembersrt:MinimumMemberus-gaap:PrimeRateMember2023-12-142023-12-140001783183us-gaap:EmployeeStockOptionMember2024-01-012024-09-300001783183phat:TwoThousandNineteenIncentiveAwardPlanMember2025-09-300001783183phat:TakedaPharmaceuticalCompanyLimitedMemberus-gaap:CommonStockMemberphat:TakedaLicenseAgreementMember2019-05-0700017831832025-04-012025-06-300001783183us-gaap:ResearchAndDevelopmentExpenseMember2024-07-012024-09-300001783183us-gaap:CommonStockMemberus-gaap:OverAllotmentOptionMember2024-08-200001783183us-gaap:RetainedEarningsMember2025-09-300001783183phat:StockOptionsAndRestrictedStockUnitMemberphat:TwoThousandNineteenIncentiveAwardPlanMember2025-01-012025-09-300001783183phat:RebatesReturnsAndCo-PayAssistanceMember2024-12-310001783183phat:LoanAgreementMemberphat:TermLoansAggregatePrincipalAmountTranchesTwoMember2023-12-140001783183phat:ThreeCustomersMembersrt:MinimumMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2025-01-012025-09-300001783183phat:PriorToThreeMonthsTrailingMemberphat:LoanAgreementMembersrt:MaximumMember2023-12-142023-12-140001783183us-gaap:AdditionalPaidInCapitalMember2024-03-310001783183us-gaap:SellingGeneralAndAdministrativeExpensesMember2025-07-012025-09-300001783183phat:LoanAgreementMemberphat:TermLoansAggregatePrincipalAmountTranchesTwoMember2021-09-170001783183us-gaap:RestrictedStockUnitsRSUMember2025-01-012025-09-300001783183us-gaap:PerformanceSharesMember2025-07-012025-09-300001783183srt:MinimumMemberus-gaap:OverAllotmentOptionMember2024-08-200001783183phat:ShareBasedPaymentArrangementEmployeeAndNonemployeeMember2024-01-012024-09-300001783183phat:ThreeCustomersMembersrt:MinimumMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueProductLineMember2024-01-012024-09-300001783183phat:EmployeeStockPurchasePlanMember2019-10-310001783183us-gaap:OverAllotmentOptionMember2024-07-012024-09-3000017831832024-01-012024-03-310001783183phat:LoanAgreementMembersrt:MaximumMember2023-12-140001783183us-gaap:RetainedEarningsMember2025-03-3100017831832024-04-012024-06-300001783183phat:LoanAgreementMemberphat:TermLoansAggregatePrincipalAmountTranchesThreeMember2024-06-140001783183phat:InitialInvestorsAndCoFinanceLVSXXXVIILLCAndHerculesMemberphat:JoinderAgreementMember2022-10-310001783183phat:TermLoanFirstAdvanceMemberphat:LoanAgreementMember2025-09-300001783183us-gaap:BaseRateMemberphat:LoanAgreementMemberphat:TermLoanMembersrt:MaximumMember2023-12-140001783183stpr:NJ2025-01-012025-09-300001783183phat:LoanAgreementMemberphat:TermLoansAggregateFiveAdditionalTranchesMember2023-12-140001783183phat:VoqueznaProductMember2025-01-012025-09-3000017831832025-09-300001783183phat:LoanAgreementMemberphat:ThreeMonthsTrailingMember2023-12-142023-12-140001783183us-gaap:AccountsReceivableMember2024-01-012024-12-310001783183phat:TermLoanMemberphat:LoanAgreementMembersrt:MaximumMember2023-12-14iso4217:EURphat:Customersxbrli:purephat:Employeephat:Optionxbrli:sharesiso4217:USDxbrli:sharesphat:Segmentiso4217:USD

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2025

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to .

Commission File Number: 001-39094

PHATHOM PHARMACEUTICALS, INC.

(Exact name of Registrant as specified in its charter)


Delaware		82-4151574
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

100 Campus Drive, Suite 102 Florham Park, New Jersey		07932
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (877) 742-8466

Securities registered pursuant to Section 12(b) of the Act:

     Title of each class

     Trading
Symbol(s)

     Name of each exchange on which registered

     Common Stock, $0.0001 par value per share

     PHAT

     The Nasdaq Global Select Market

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☑ No ☐

Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files). Yes ☑ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☑	Smaller reporting company	☑
Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☑

As of October 27, 2025, the registrant had 71,138,440 shares of common stock ($0.0001 par value) outstanding.

TABLE OF CONTENTS


PART I. FINANCIAL INFORMATION

Item 1	Financial Statements (unaudited)	F-1
	Condensed Balance Sheets	F-1
	Condensed Statements of Operations and Comprehensive Loss	F-2
	Condensed Statements of Stockholders’ Deficit	F-3
	Condensed Statements of Cash Flows	F-5
	Notes to Condensed Unaudited Financial Statements	F-6
Item 2	Management’s Discussion and Analysis of Financial Condition and Results of Operations	22
Item 3	Quantitative and Qualitative Disclosures About Market Risk	33
Item 4	Controls and Procedures	33

PART II. OTHER INFORMATION

Item 1	Legal Proceedings	35
Item 1A	Risk Factors	35
Item 2	Unregistered Sales of Equity Securities and Use of Proceeds	35
Item 3	Defaults Upon Senior Securities	35
Item 4	Mine Safety Disclosures	35
Item 5	Other Information	35
Item 6	Exhibits	36
	Signatures	38

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements (unaudited)

PHATHOM PHARMACEUTICALS, INC.

Condensed Balance Sheets

(Unaudited)

(in thousands, except share and par value amounts)


	September 30, 2025			December 31, 2024
Assets
Current assets:
Cash and cash equivalents	$	135,156		$	297,263
Prepaid expenses and other current assets		13,227			20,866
Accounts receivable, net		55,789			38,797
Inventory		3,611			3,208
Total current assets		207,783			360,134
Property and equipment, net		1,156			1,476
Operating lease right-of-use assets		2,694			613
Restricted cash		2,862			2,862
Inventory, non-current		24,101			11,540
Other long-term assets		1,693			1,693
Total assets	$	240,289		$	378,318
Liabilities and Stockholders’ Deficit
Current liabilities:
Accounts payable	$	1,075		$	10,507
Accrued expenses		65,349			53,232
Accrued interest		1,764			1,711
Operating lease liabilities, current		591			501
Current portion of revenue interest financing liability		24,344			19,777
Total current liabilities		93,123			85,728
Long-term debt, net of discount		207,093			201,409
Revenue interest financing liability		348,984			333,261
Operating lease liabilities		2,123			—
Other long-term liabilities		11,500			11,500
Total liabilities		662,823			631,898
Commitments and contingencies (Note 3)
Stockholders’ deficit:
Preferred stock, $0.0001 par value; authorized shares — 40,000,000 at September 30, 2025 and December 31, 2024; no shares issued and outstanding at September 30, 2025 and December 31, 2024		—			—
Common stock, $0.0001 par value; authorized shares — 400,000,000 at September 30, 2025 and December 31, 2024; issued and outstanding shares — 71,043,149 and 68,518,238 at September 30, 2025 and December 31, 2024, respectively		6			6
Treasury stock — 19 shares at September 30, 2025 and December 31, 2024		—			—
Additional paid-in capital		1,040,570			1,009,425
Accumulated deficit		(1,463,110	)		(1,263,011	)
Total stockholders’ deficit		(422,534	)		(253,580	)
Total liabilities and stockholders’ deficit	$	240,289		$	378,318

See accompanying notes.

F-1

PHATHOM PHARMACEUTICALS, INC.

Condensed Statements of Operations and Comprehensive Loss

(Unaudited)

(in thousands, except share and per share amounts)


	Three Months Ended September 30,						Nine Months Ended September 30,
	2025			2024			2025			2024
Product revenue, net	$	49,504		$	16,352		$	117,526		$	25,588
Cost of revenue		6,190			2,356			14,951			4,158
Gross profit		43,314			13,996			102,575			21,430
Operating expenses:
Research and development		7,027			8,693			25,287			25,499
Selling, general and administrative		51,558			76,099			231,346			213,981
Total operating expenses		58,585			84,792			256,633			239,480
Loss from operations		(15,271	)		(70,796	)		(154,058	)		(218,050	)
Other (expense) income:
Interest income		1,413			3,711			5,840			11,648
Interest expense		(16,108	)		(18,484	)		(51,696	)		(53,416	)
Other expense, net		(7	)		(8	)		(185	)		(57	)
Total other expense		(14,702	)		(14,781	)		(46,041	)		(41,825	)
Net loss and comprehensive loss	$	(29,973	)	$	(85,577	)	$	(200,099	)	$	(259,875	)
Net loss per share, basic and diluted	$	(0.41	)	$	(1.32	)	$	(2.76	)	$	(4.29	)
Weighted-average shares of common stock outstanding, basic and diluted		73,396,435			64,627,847			72,615,910			60,543,545

See accompanying notes.

F-2

PHATHOM PHARMACEUTICALS, INC.

Condensed Statements of Stockholders’ Deficit

(Unaudited)

(in thousands, except share amounts)


	Common Stock				Treasury Stock		Additional Paid-in			Accumulated			Total Stockholders’
	Shares		Amount		Shares		Capital			Deficit			Deficit
Balance at December 31, 2024		68,518,238	$	6		19	$	1,009,425		$	(1,263,011	)	$	(253,580	)
401(k) matching contribution		290,165		—		—		2,127			—			2,127
Vesting of restricted stock units		508,568		—		—		—			—			—
Stock-based compensation		—		—		—		5,540			—			5,540
ESPP shares issued		321,099		—		—		1,853			—			1,853
Net loss		—		—		—		—			(94,316	)		(94,316	)
Balance at March 31, 2025		69,638,070		6		19		1,018,945			(1,357,327	)		(338,376	)
Vesting of restricted stock units		456,677		—		—		—			—			—
Stock-based compensation		—		—		—		8,272			—			8,272
Issuance of common stock from exercises of stock options		9,672		—		—		80			—			80
Net loss		—		—		—		—			(75,810	)		(75,810	)
Balance at June 30, 2025		70,104,419		6		19		1,027,297			(1,433,137	)		(405,834	)
401(k) matching contribution		326,212		—		—		3,131			—			3,131
Vesting of restricted stock units and performance stock units, net of employee tax obligation		392,592		—		—		(564	)		—			(564	)
Stock-based compensation		—		—		—		9,297			—			9,297
Issuance of common stock from exercises of stock options		35,732		—		—		293			—			293
ESPP shares issued		184,194		—		—		1,116			—			1,116
Net loss		—		—		—		—			(29,973	)		(29,973	)
Balance at September 30, 2025		71,043,149	$	6		19	$	1,040,570		$	(1,463,110	)	$	(422,534	)

See accompanying notes.

F-3

PHATHOM PHARMACEUTICALS, INC.

Condensed Statements of Stockholders’ Deficit

(Unaudited)

(in thousands, except share amounts)


	Common Stock				Treasury Stock		Additional Paid-in		Accumulated			Total Stockholders’
	Shares		Amount		Shares		Capital		Deficit			Deficit
Balance at December 31, 2023		57,970,044	$	5		19	$	855,921	$	(928,685	)	$	(72,759	)
401(k) matching contribution		93,736		—		—		712		—			712
Vesting of restricted stock units		340,542		—		—		—		—			—
Stock-based compensation		—		—		—		5,626		—			5,626
ESPP shares issued		119,779		—		—		770		—			770
Net loss		—		—		—		—		(82,852	)		(82,852	)
Balance at March 31, 2024		58,524,101		5		19		863,029		(1,011,537	)		(148,503	)
Vesting of restricted stock units		74,492		—		—		—		—			—
Stock-based compensation		—		—		—		6,099		—			6,099
Issuance of common stock from exercise of stock options		2,432		—		—		21		—			21
Net loss		—		—		—		—		(91,446	)		(91,446	)
Balance at June 30, 2024		58,601,025		5		19		869,149		(1,102,983	)		(233,829	)
401(k) matching contribution		289,853		—		—		2,971		—			2,971
Vesting of restricted stock units		454,003		—		—		—		—			—
Stock-based compensation		—		—		—		5,635		—			5,635
ESPP shares issued		255,602		—		—		1,631		—			1,631
Issuance of common stock and pre-funded warrants in connection with the underwritten public offering, net		8,695,652		1		—		121,774		—			121,775
Issuance of common stock from exercise of stock options		27,803		—		—		282		—			282
Net loss		—		—		—		—		(85,577	)		(85,577	)
Balance at September 30, 2024		68,323,938	$	6		19	$	1,001,442	$	(1,188,560	)	$	(187,112	)

See accompanying notes.

F-4

PHATHOM PHARMACEUTICALS, INC.

Condensed Statements of Cash Flows

(Unaudited)

(in thousands)


	Nine Months Ended September 30,
	2025			2024
Cash flows from operating activities
Net loss	$	(200,099	)	$	(259,875	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		505			602
Stock-based compensation		23,109			17,360
Issuance of PIK interest debt		3,479			2,724
Accrued interest on revenue interest financing liability		20,290			35,656
Amortization of debt discount		2,205			1,563
Inventory reserve		819			716
Other		4,340			4,202
Changes in operating assets and liabilities:
Prepaid expenses and other current assets		7,638			(1,784	)
Accounts receivable, net		(16,992	)		(19,415	)
Accounts payable and accrued expenses		6,530			14,993
Accrued interest		53			376
Operating right-of-use assets and lease liabilities		132			134
Inventory		(13,783	)		(566	)
Net cash used in operating activities		(161,774	)		(203,314	)
Cash flows from investing activities
Cash paid for property and equipment		(142	)		(130	)
Net cash used in investing activities		(142	)		(130	)
Cash flows from financing activities
Proceeds from issuance of common stock from exercise of stock options		373			303
Net proceeds from issuance of debt		—			34,650
Net proceeds from underwritten public offering		—			121,775
Payment of employee tax obligations related to vesting of performance stock units		(564	)		—
Net cash (used in) provided by financing activities		(191	)		156,728
Net decrease in cash and cash equivalents and restricted cash		(162,107	)		(46,716	)
Cash and cash equivalents and restricted cash – beginning of period		300,125			384,256
Cash and cash equivalents and restricted cash – end of period	$	138,018		$	337,540

Supplemental disclosure of cash flow information
Interest paid	$	15,938		$	12,478
Supplemental disclosure of noncash investing and financing activities:
Property and equipment purchases included in accounts payable and accrued expenses	$	51		$	—
Final interest payment fee	$	—		$	1,050
Settlement of ESPP liability in common stock	$	2,969		$	2,401
Settlement of 401(k) liability in common stock	$	5,258		$	3,683

See accompanying notes.

F-5

PHATHOM PHARMACEUTICALS, INC.

Notes to Condensed Unaudited Financial Statements

1. Organization, Basis of Presentation and Summary of Significant Accounting Policies

Organization

Phathom Pharmaceuticals, Inc., or the Company or Phathom, was incorporated in the state of Delaware in January 2018. The Company is a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases.

In May 2022, the U.S. Food and Drug Administration, or FDA, approved the the Company's new drug applications, or NDAs for vonoprazan triple therapy, under the brand name VOQUEZNA TRIPLE PAK, and vonoprazan dual therapy, under the brand name VOQUEZNA DUAL PAK. On October 27, 2023, the FDA approved the prior approval supplements to the Company's NDAs, for VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK. Additionally, on November 1, 2023, the FDA approved the Company's NDA for VOQUEZNA tablets. The Company initiated commercial launch for VOQUEZNA in the U.S. for both the Erosive GERD and H. pylori indications, and VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK for treatment of H. pylori infection in the fourth quarter of 2023. Additionally, on July 17, 2024, the FDA approved VOQUEZNA 10 mg tablets for the relief of heartburn associated with Non-Erosive GERD.

Liquidity and Capital Resources

From inception to September 30, 2025, the Company has devoted substantially all of its efforts to organizing and staffing the Company, business planning, raising capital, in-licensing its initial and approved product candidate, vonoprazan, meeting with regulatory authorities, managing the clinical trials of vonoprazan, preparing for commercialization of its initial products containing vonoprazan, commercially launching its approved products in the U.S., and providing other selling, general and administrative support for these operations. The Company has a limited operating history as a commercial company, has generated limited product revenue to date, and the sales and income potential of its business remains uncertain. The Company has incurred net losses and negative cash flows from operating activities since its inception and despite the Company's plans and expectations, could continue to incur additional net losses in the future. The Company has funded its operations primarily through commercial bank debt, the revenue interest financing debt and various equity offerings, including the Company's at-the-market, or ATM, offerings. From inception through September 30, 2025, the Company sold 34,737,032 shares of common stock and 2,608,922 pre-funded warrants, generating net proceeds of approximately $543.3 million, after deducting underwriting discounts, commissions and offering costs.

The accompanying unaudited interim condensed financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or amounts and classification of liabilities in accordance with U.S. generally accepted accounting principles, or GAAP. Management is required to perform a two-step analysis of the Company’s ability to continue as a going concern. Management must first evaluate whether there are conditions and events that raise substantial doubt about the Company’s ability to continue as a going concern (Step 1). If management concludes that substantial doubt is raised, management is also required to consider whether its plans alleviate that doubt (Step 2).

Management believes that it has sufficient working capital on hand to fund operations through at least the next twelve months from the date these unaudited interim condensed financial statements were issued. There can be no assurance that the Company will be successful in acquiring additional funding, if needed, that the Company’s projections of its future working capital needs will prove accurate, or that any additional funding would be sufficient to continue operations in future years.

Basis of Presentation

The unaudited interim condensed financial statements included herein have been prepared by the Company in accordance with GAAP, and pursuant to the rules and regulations of the Securities and Exchange Commission, or the SEC. In the opinion of management, the accompanying unaudited interim condensed financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to present fairly the Company’s financial position, results of operations, and cash flows. The interim results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information in the footnote disclosures of the financial statements has been condensed or omitted where it substantially duplicates information provided in the Company’s latest audited financial statements, in accordance with the rules and regulations of the SEC. These unaudited interim condensed financial statements should be read in conjunction with the Company’s audited financial statements and footnotes included

F-6

in its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, or the 2024 Form 10-K, filed with the SEC on March 7, 2025.

During the nine months ended September 30, 2025, there were no significant changes to the Company’s summary of significant accounting policies contained in the Company’s 2024 Form 10-K. The Company’s complete listing of significant accounting policies is set forth in Note 1 of the notes to the audited financial statements in the Company's 2024 Form 10-K. Selected significant accounting policies are discussed in detail below.

Use of Estimates

The preparation of the Company’s unaudited condensed interim financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses, and the disclosure of contingent assets and liabilities in the Company’s unaudited condensed interim financial statements and accompanying notes. The most significant estimates in the Company’s unaudited condensed interim financial statements relate to accruals for net product revenues and the valuation for the revenue interest financing liability. In addition, management’s assessment of the Company’s ability to continue as a going concern involves the estimation of the amount and timing of future cash inflows and outflows. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results could differ materially from those estimates and assumptions.

Fair Value Measurements

The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or non-recurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:

Level 1: Observable inputs such as quoted prices in active markets.

Level 2: Inputs, other than the quoted prices in active markets that are observable either directly or indirectly.

Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

The carrying amounts of the Company’s financial instruments, including cash and cash equivalents, are classified within the Level 1 designation discussed above, while accounts receivable, prepaid and other current assets, accounts payable, and accrued liabilities, approximate fair value due to their short maturities.

The Company has no financial assets measured at fair value on a recurring basis. None of the Company’s non-financial assets or liabilities are recorded at fair value on a non-recurring basis. No transfers between levels have occurred during the periods presented.

As of September 30, 2025 and December 31, 2024, the estimated fair value of the Company’s long-term debt approximated the carrying amount given its floating interest rate basis. The fair value of the Company’s long-term debt was estimated for disclosure purposes only and was determined based on quoted market data for valuation, and thus categorized as Level 2 in the fair value hierarchy.

Concentrations of Credit Risk

Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.

The Company is also subject to credit risk from our accounts receivable related to our product sales. The Company monitors exposure within accounts receivable and records an allowance for credit losses as necessary. The Company extends credit primarily to wholesale distributors. Customer creditworthiness is monitored and collateral is not required. The allowance for credit losses reflects the best estimate of expected credit losses of the accounts receivable portfolio determined on the basis of historical experience, current

F-7

information, and forecasts of future economic conditions. The Company determines its allowance methodology by pooling receivable balances at the customer level. The Company considers various factors, including its previous loss history, individual credit risk associated with each customer, and the current and future conditions of the general economy. These credit risk factors are monitored on a quarterly basis and updated as necessary. To the extent that any individual debtor is identified whose credit quality has deteriorated, the Company establishes allowances based on the individual risk characteristics of such customer. The Company makes concerted efforts to collect all outstanding balances due from customers; however, account balances are charged off against the allowance when management believes it is probable the receivable will not be recovered. The Company does not have any off-balance-sheet credit exposure related to customers.

As of September 30, 2025, three customers accounted for 86% of the accounts receivable balance, with each of these individual customers ranging from 27% to 30% of the accounts receivable balance. As of December 31, 2024, three customers accounted for 81% of the accounts receivable balance, with each of these individual customers ranging from 25% to 31% of the accounts receivable balance. For the three and nine months ended September 30, 2025, three customers accounted for 70% of the product sales in each period, with each of these individual customers ranging from 22% to 25% of the product sales in both periods. For the three and nine months ended September 30, 2024, three customers accounted for 70% and 68% of the product sales, respectively, with each of these individual customers ranging from 22% to 24% of the product sales in both periods.

Net Loss Per Share

Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding and pre-funded warrants for the period, without consideration for other potentially dilutive securities. For the three and nine months ended September 30, 2025, basic shares outstanding includes the weighted average effect of the Company’s outstanding pre-funded warrants, the exercise of which requires little or no consideration for the delivery of shares of common stock. For the three and nine months ended September 30, 2025 and 2024, the Company had no weighted-average unvested shares to exclude from the weighted-average number of common shares outstanding. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and dilutive common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. Dilutive common stock equivalents are comprised of unvested common stock, options and warrants. For the periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as inclusion of the potentially dilutive securities (warrants, stock options, and restricted stock units) would be antidilutive.

Recently Adopted Accounting Standards

In December 2023, the FASB issued ASU 2023-09 – Income Taxes (Topic 740) – Improvements to Income Tax Disclosures, which improves income tax disclosures primarily relating to the rate reconciliation and income taxes paid information. This includes a tabular reconciliation using both percentages and reporting currency amounts, covering various tax and reconciling items, and disaggregated summaries of income taxes paid during the period. For public business entities, the guidance is effective for annual periods beginning after December 15, 2024, with early adoption permitted. The update will be effective for the Company beginning with its 2025 annual financial statements. The Company currently expects that this standard will not have a material impact on the footnote disclosures to its annual financial statements.

Recently Issued Accounting Pronouncements

The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board or other standard setting bodies on the Company's financial statements as well as material updates to previous assessments, if any, from the Company’s 2024 Form 10-K. There were no new material accounting standards issued in the third quarter of 2025 that impacted the Company.

F-8

2. Balance Sheet Details

Accrued Expenses

Accrued expenses consist of the following (in thousands):


	September 30,		December 31,
	2025		2024
Accrued compensation expenses	$	14,798	$	16,659
Accrued professional & consulting expenses		305		1,203
Accrued research and development expenses		1,355		2,339
Accrued revenue allowances		44,098		29,987
Accrued other		4,793		3,044
Total accrued expenses	$	65,349	$	53,232

Inventory

Inventory consist of the following (in thousands):


	September 30,		December 31,
	2025		2024
Finished goods	$	2,603	$	1,479
Raw materials		1,008		1,729
Total inventory, current		3,611		3,208
Raw materials, non-current		24,101		11,540
Total inventory	$	27,712	$	14,748

Raw materials consist of materials, including active pharmaceutical ingredients, to be consumed in the production of inventory related to FDA-approved products. Inventory that is used for clinical development purposes is expensed to research and development expense when consumed. Inventory, noncurrent includes inventory expected to remain on-hand beyond one year from the balance sheet dates presented.

3. Commitments and Contingencies

License Agreement

On May 7, 2019, the Company entered into a license agreement with Takeda pursuant to which it was granted an exclusive license to commercialize vonoprazan fumarate in the United States, Canada and Europe, or the Takeda License. The Company also has the right to sublicense its rights under the agreement, subject to certain conditions. The agreement will remain in effect, on a country-by-country and product-by-product basis, until the later of (i) the expiration of the last to expire valid patent claim covering vonoprazan fumarate alone or in combination with at least one other therapeutically active ingredient, (ii) the expiration of the applicable regulatory exclusivity and (iii) 15 years from the date of first commercial sale, unless earlier terminated. The Company may terminate the Takeda License upon six months’ written notice. The Company and Takeda may terminate the Takeda License in the case of the other party’s insolvency or material uncured breach. Takeda may terminate the Takeda License if the Company challenges, or assists in challenging, licensed patents.

In consideration of the Takeda License, the Company (i) paid Takeda $25 million in cash, (ii) issued Takeda 1,084,000 shares of its common stock at a fair value of $5.9 million, (iii) issued the Takeda Warrant to purchase 7,588,000 shares of its common stock at an exercise price of $0.00004613 per share at an initial fair value of $47.9 million, and (iv) issued a right to receive an additional common stock warrant, or the Takeda Warrant Right, should Takeda’s fully-diluted ownership of the Company represent less than a certain specified percentage of the fully-diluted capitalization, including shares issuable upon conversion of then outstanding convertible promissory notes, calculated immediately before the closing of the Company’s initial public offering, or IPO, with a nominal initial fair value due to the low probability of issuance. The Takeda Warrant Right expired without effect since no fair value had been allocated to it upon completion of the IPO, and no additional warrant was issued. In addition, the Company is obligated to pay Takeda up to an aggregate of $250 million in sales milestones upon the achievement of specified levels of product sales, and a low double-digit royalty rate on aggregate net sales of licensed products, subject to certain adjustments. The Takeda Warrant had an exercise price of

F-9

$0.00004613 per share, and was to expire on May 7, 2029 and became exercisable upon the consummation of the IPO. All Takeda Warrants were exercised by March 2022.

During the three months ended September 30, 2025 and 2024, the Company recorded $5.0 million and $1.6 million, respectively, of royalty expense under the Takeda License, of which $5.0 million is included within accrued expenses as of September 30, 2025. During the nine months ended September 30, 2025 and 2024, the Company recorded $11.8 million and $2.6 million, respectively, of royalty expense under the Takeda License.

Purchase Commitments

In December 2020, the Company entered into a supply agreement with Sandoz pursuant to which Sandoz has agreed to supply commercial quantities of amoxicillin capsules and clarithromycin tablets, package these antibiotics with vonoprazan, and provide in finished convenience packs. The supply agreement commits the Company to a minimum purchase obligation of €2.9 million, or approximately $3.4 million, in the first 24-month period following the launch of the final product. The Company incurred $1.5 million and $1.7 million under the agreement during the three and nine months ended September 30, 2025, respectively. The Company incurred $0.3 million under the agreement during the three and nine months ended September 30, 2024. As of September 30, 2025, approximately €1.2 million, or approximately $1.4 million, of the minimum purchase obligation remains and for which the Company has recorded within accrued expenses on the condensed balance sheets and within the Company’s condensed consolidated statement of operations and comprehensive loss during the three months ended September 30, 2025.

The Company had previously been informed by Sandoz that there could be a disruption in the supply of clarithromycin tablets, a component of the VOQUEZNA TRIPLE PAK. Given more recent communications, however, the Company does not currently anticipate any near-term supply issues. The Company plans to continue to actively monitor the situation to determine if a supply disruption may still arise in the future. The VOQUEZNA TRIPLE PAK represents approximately 1% of our total revenue. While the Company has not experienced any commercial disruption to date, any disruption for such supply would result in our inability to continue to commercialize the VOQUEZNA TRIPLE PAK. The VOQUEZNA bottles and the VOQUEZNA DUAL PAKs are not impacted, as they do not include clarithromycin.

Contingencies

In the event the Company becomes subject to claims or suits arising in the ordinary course of business, the Company would accrue a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.

4. Lease Commitments

As of September 30, 2025, the Company had operating leases for office space in both Buffalo Grove, Illinois and Florham Park, New Jersey, with weighted average remaining lease terms of 4.7 years and 5.4 years, respectively. In September 2025, the Company entered into amendments to its lease agreements for the New Jersey office space to extend the terms of the leases through February 2031. All operating leases contain an option to extend the term for one additional five year period, which was not considered in the determination of the right-of-use asset or lease liability as the Company did not consider it reasonably certain that it would exercise such options.

The total rent expense for the three months ended September 30, 2025 and 2024 was $0.2 million and 0.3 million, respectively. Total rent expense for each of the nine months ended September 30, 2025 and 2024 was $0.8 million. Total short-term lease costs relating to leased vehicles were approximately $1.6 million and $2.1 million for the three months ended September 30, 2025 and 2024, respectively. Total short-term lease costs relating to leased vehicles were approximately $5.2 million and $7.1 million for the nine months ended September 30, 2025 and 2024, respectively.

F-10

As of September 30, 2025, the future minimum annual lease payments under the operating leases were as follows (in thousands):


Year ending December 31:
2025	$	90
2026		686
2027		719
2028		736
2029		753
2030		702
Thereafter		100
Total minimum lease payments		3,786
Less: amount representing interest		(1,072	)
Present value of operating lease liabilities		2,714
Less: operating lease liabilities, current		(591	)
Operating lease liabilities, non-current	$	2,123

Weighted-average remaining lease term (in years)		5.24
Weighted-average incremental borrowing rate		13.83	%

Operating cash flows for the nine months ended September 30, 2025 and 2024 included cash payments for operating leases of approximately $0.6 million and $0.7 million, respectively.

5. Debt

Total debt consists of the following (in thousands):


	September 30,			December 31,
	2025			2024
Long-term debt, current portion	$	—		$	—
Long-term debt, non-current portion		215,310			211,831
Unamortized debt discount		(8,217	)		(10,422	)
Total debt, net of debt discount	$	207,093		$	201,409

On September 17, 2021, or the Closing Date, the Company entered into a Loan and Security Agreement, or, the Loan Agreement, with Hercules Capital, Inc., or Hercules, in its capacity as administrative agent and collateral agent and as a lender, or, in such capacity, the Agent or Hercules, and the other financial institutions that from time to time become parties to the Loan Agreement as lenders, or, collectively, the Lenders.

The Loan Agreement provides for term loans in an aggregate principal amount of up to $200 million, or the Term Loan, under multiple tranches. The tranches consist of (i) a first tranche consisting of term loans in an aggregate principal amount of $100 million, all of which was funded on the Closing Date, or the First Advance, (ii) a second tranche consisting of up to an additional $50 million, (iii) a third and fourth tranches consisting of an additional total $50 million, which became available in May 2022.

On September 27, 2022, the Company entered into an amendment to the Loan Agreement, or the Second Loan Amendment, pursuant to which the date the second tranche of funding of $50 million was to remain available to the Company, was moved to May 15, 2023, rather than December 15, 2022.

On May 9, 2023, the Company entered into the Third Amendment to Loan and Security Agreement, or the Third Loan Amendment, with the lenders, pursuant to which, among other things, (i) the second tranche availability was extended from through May 15, 2023, to through December 15, 2023, and became available on October 1, 2023, (ii) the third tranche availability was extended from through September 30, 2023, to through December 15, 2023, and became available on October 1, 2023, (iii) the effective date of the performance covenants was amended to provide an option to extend the covenant trigger date to May 15, 2024, subject to the achievement of the FDA approval of vonoprazan for Erosive GERD or the EE Milestone, prior to February 15, 2024, and (iv) the warrant agreement with Hercules was amended as described below. On November 1, 2023, the EE Milestone was achieved and the covenant trigger date was extended to May 15, 2024. In connection with the Third Loan Amendment, a tranche extension amendment fee of

F-11

$150,000 and a covenant extension amendment fee of $100,000 was paid to the Agent. These fees have been recorded as debt discount and are being amortized to interest expense using the effective interest method over the remaining term of the Term Loan.

On December 14, 2023, the Company entered into a Fourth Amendment to Loan and Security Agreement, or the Fourth Loan Amendment, with the lenders, which, among other things, (i) increased the aggregate principal amount of the term loans from $200 million to $300 million; (ii) provided for the possibility of accessing the remaining $200 million commitment through five tranches referred to as the second through sixth tranches, which are available subject to certain milestones and conditions: (a) Second Tranche: $50 million, $40 million of which was funded on December 14, 2023, and the remaining $10 million of which was funded on March 15, 2024, (b) Third Tranche: $25 million which was funded on June 14, 2024, (c) Fourth Tranche: $25 million which was funded on December 15, 2024, (d) Fifth Tranche: $50 million which was available, subject to the achievement of a specified revenue milestone, or the Fifth Tranche milestone, through June 30, 2025 and which the Company did not draw down, and (e) Sixth Tranche: $50 million available, subject to the achievement of a specific revenue milestone, or the Sixth Tranche milestone, through December 31, 2025; (iii) extended the interest only period and the maturity date from October 2026 to December 2027, (iv) reduced the cash interest rate from 10.75% (floating annual rate equal to the greater of (a) 5.50% and (b) the Prime Rate (as reported in the Wall Street Journal) plus 2.25% to 9.85% (floating rate based on the greater of (a) 9.85% or (b) US WSJ Prime + 1.35%), provided that the cash interest rate shall be capped at 10.35% and upon the Company achieving the Sixth Tranche milestone, the cash interest floating rate shall be decreased by 0.35% to 9.50%, and (v) decreased the payment-in-kind interest rate from 3.35% per annum to 2.15% per annum. In connection with the Fourth Loan Amendment, an amendment fee of $250,000 was paid to the Agent and was recorded as a debt discount and is being amortized to interest expense using the effective interest method over the remaining term of the Term Loan.

The Term Loan will mature on December 1, 2027, or the Maturity Date. The Term Loan bears (i) cash interest at a variable annual rate equal to the greater of (a) 9.85% and (b) the Prime Rate (as reported in the Wall Street Journal) plus 1.35%, or the Interest Rate, and (ii) payment-in-kind interest at a per annum rate of interest equal to 2.15%. The Company may make payments of interest only through the Maturity Date. After the interest-only period, the principal balance and related interest will be required to be repaid in full on the Maturity Date.

In addition, the Company is obligated to pay a final payment fee of 7.50% of the original principal amount of amounts actually advanced under the Term Loan, or each a Term Loan Advance and together, the Term Loan Advances. In connection with the Fourth Loan Amendment, the final payment fee was amended to be $1 million plus 3.00% of any future tranche drawdowns under the agreement, due upon final maturity. Additionally, the initial final payment fee for the first Term Loan Advance was amended to become payable on October 1, 2026. As of September 30, 2025, the aggregate $11.5 million of final payment fees includes the first Term Loan Advance of $7.5 million, $2.5 million for the second Term Loan Advance, $0.8 million for the third Term Loan Advance, and $0.7 million for the fourth Term Loan Advance and have been recorded within other long-term liabilities.

Under the Fourth Loan Amendment the Company may elect to prepay all or a portion of the Term Loan Advances prior to maturity, subject to a prepayment fee of up to 1.25% of the then outstanding principal balance of the Term Loan Advances being prepaid when such prepayment occurs prior to October 1, 2026, or 0.50% if such prepayment occurs on or after October 1, 2026. After repayment, no Term Loan amounts may be borrowed again.

As collateral for the obligations, the Company has granted to Hercules a senior security interest in all of Company’s right, title, and interest in, to and under substantially all of Company’s property, inclusive of intellectual property.

The Loan Agreement contains customary closing fees, prepayment fees and provisions, events of default, and representations, warranties and covenants, including financial covenants. The financial covenants under the Fourth Loan Amendment include (i) a minimum cash covenant and (ii) a performance covenant as follows:

(i)

Minimum cash covenant - The Company must maintain a minimum cash balance of 20% of the outstanding principal balance at all times. The minimum cash balance may be increased to 35% or 50% under performance covenant (b) below if the performance covenants (a) or (c) are not met beginning September 30, 2024 and all times thereafter.

(ii)

Performance covenant - Beginning September 30, 2024 and all times thereafter the Company must satisfy any one of the following:

Market capitalization exceeding $900 million;

Minimum cash balance exceeding (x) outstanding principal amount of term loans, multiplied by (y) (A) 50%, prior to achieving trailing three months net product revenue of greater than $35 million, and (B) 35% thereafter; or

F-12

Trailing three months net product revenue of at least (x) 30% of agreed upon projected net revenues for periods in the calendar year 2024 and 25% for all periods thereafter or (y) $120 million.

Upon the occurrence of an event of default, subject to any specified cure periods, all amounts owed by the Company may be declared immediately due and payable by Hercules, as collateral agent.

As of September 30, 2025, the Company was in compliance with all applicable covenants under the Loan Agreement. Based on the Company’s current revenue projections, the Company does not expect to meet the revenue threshold to draw the Sixth Tranche. The Company’s current operating plan does not anticipate a need to draw any additional amounts under the Loan Agreement.

In connection with the entry into the Loan Agreement, the Company issued to Hercules a warrant, or the Warrant, to purchase a number of shares of the Company’s common stock equal to 2.5% of the aggregate amount of the Term Loan advances funded, and will issue to Hercules additional warrants if any future Term Loan advances are funded. On the Closing Date, the Company issued a Warrant for 74,782 shares of common stock. The Warrant will be exercisable for a period of seven years from the date of issuance at a per-share exercise price equal to $33.43, which was the closing price of the Company’s common stock on September 16, 2021. In connection with the entry into the Third Loan Amendment, the Company amended the form of warrants to be issued upon drawdowns of future tranches such that the exercise price of such warrants shall be equal to the lesser (i) of $11.6783, which was the trailing ten-day VWAP prior to entering into the Third Loan Amendment and (ii) the trailing ten-day VWAP preceding the date on which the Company drawdown future tranches. In connection with the entry into the Fourth Loan Amendment, the Company eliminated the warrant agreement for all future tranches. The Warrant issued with the initial tranche was not modified as part of this amendment. The exercise price and terms of the outstanding Warrant remain unchanged.

The initial $1.3 million fair value of the Warrant, the $11.5 million final interest payment fees and $4.6 million of debt issuance costs have been recorded as debt discount and are being amortized to interest expense using the effective interest method over the term of the Loan Agreement.

Future minimum principal payments under the Term Loan, including the final payment fee, as of September 30, 2025 are as follows (in thousands):


Year ending December 31:
2025	$	—
2026		7,500
2027		229,706
Total principal and interest payments		237,206
Less: payment-in-kind and final payment fee		(37,206	)
Total term loan borrowings	$	200,000

During the three months ended September 30, 2025 and 2024, the Company recognized $7.4 million and $6.3 million, respectively, of interest expense, including amortization of the debt discount, in connection with the Loan Agreement. During the nine months ended September 30, 2025 and 2024, the Company recognized $21.6 million and $16.8 million, respectively, of interest expense, including amortization of the debt discount, in connection with the Loan Agreement. As of September 30, 2025, the Company had an outstanding loan balance of $215.3 million and accrued interest of $1.8 million.

6. Revenue Interest Financing Liability

On May 3, 2022, the Company entered into a Revenue Interest Financing Agreement with Initial Investors NovaQuest Capital Management, or NQ, Sagard Holdings Manager LP, or Sagard, and Hercules pursuant to which the Company had the right to receive up to $260 million in funding from the Initial Investors. Under the terms of the Revenue Interest Financing Agreement, the Company received $100 million at the initial closing and received an additional $160 million upon FDA approval of VOQUEZNA for treatment of Erosive GERD during the fourth quarter of 2023.

Additionally, on October 31, 2022, the Company entered into a Joinder Agreement with the Initial Investors and CO Finance LVS XXXVII LLC, or the Additional Investor, and Hercules, together as the investors. Under the terms of the Joinder Agreement, the Company received $15 million in additional funding upon FDA approval of vonoprazan for Erosive GERD, or Approval Additional Funding, during the fourth quarter of 2023, and provided for $25 million in additional funding for achievement of a sales milestone, or Milestone Additional Funding, and, together with the Approval Additional Funding, or the Additional Investor Funding. The Initial Investors waived their rights of first offer regarding the Additional Investor Funding and the Additional Investor and joined the Revenue Interest Financing

F-13

Agreement to extend commitments for the Additional Investor Funding. On December 23, 2024, CO Finance LVS XXXVII LLC agreed to assign and transfer to OC III LVS LX LP all of its rights, title and interest as an Additional Investor and in connection therewith, OC III LVS LX LP executed a Joinder Agreement. The total amount funded by the Initial Investors and any subsequent investors is referred to herein as the Investment Amount. As of September 30, 2025, no additional funding is available under the Revenue Interest Financing Agreement.

Under the Revenue Interest Financing Agreement, the investors are entitled to receive a 10% royalty on net sales of products containing vonoprazan. The royalty rate is subject to a step-down on net sales exceeding certain annual thresholds and when the Company received FDA approval for vonoprazan for an indication relating to the treatment of heartburn associated with Non-Erosive GERD, which occurred on July 17, 2024. The investors’ right to receive royalties on net sales will terminate when the investors have aggregate payments equal to 200% of the Investment Amount. In addition, at any time after April 30, 2024, the Company has the right to make a cap payment equal to 200% of the Investment Amount less any royalties already paid, at which time the agreement will terminate.

If the investors have not received aggregate payments of at least 100% of the Investment Amount by December 31, 2028, and at least 200% of the Investment Amount by December 31, 2037, each a Minimum Amount, then the Company will be obligated to make a cash payment to the investors in an amount sufficient to gross the investors up to the applicable Minimum Amount.

Upon the occurrence of an event of default taking place between April 1, 2025 and April 1, 2028, or after April 1, 2028, the Company is obligated to pay 1.30 times Investment Amount, 1.65 times Investment Amount, and 2.0 times investment amount, respectively, less any amounts the Company previously paid pursuant to the agreement.

The Company has evaluated the terms of the Revenue Interest Financing Agreement and concluded that the features of the Investment Amount are similar to those of a debt instrument. Accordingly, the Company has accounted for the transaction as a debt obligation with interest expense based on an imputed effective rate derived from the initial carrying value of the obligation and the expected future payments. The Company recalculates the effective interest rate each period based on the current carrying value and the revised estimated future payments. As of September 30, 2025, the effective interest rate of the revenue interest financing liability was approximately 9.26%. Changes in future payments from previous estimates are included in the current and future interest expense. The carrying value of the revenue interest financing liability was $373.3 million and $353.0 million as of September 30, 2025 and December 31, 2024, respectively.

Total revenue interest financing liability consists of the following (in thousands):


Liability balance as of January 1, 2024	$	306,927
Proceeds from the Revenue Interest Financing Agreement		—
Less: transaction costs		—
Less: royalty payments and payables		(2,627	)
Plus: interest expense		48,738
Ending liability balance as of December 31, 2024		353,038
Less: current portion		(19,777	)
Long-term liability balance as of December 31, 2024	$	333,261

Liability balance as of January 1, 2025	$	353,038
Proceeds from the Revenue Interest Financing Agreement		—
Less: transaction costs		—
Less: royalty payments and payables		(9,768	)
Plus: interest expense		30,058
Ending liability balance as of September 30, 2025		373,328
Less: current portion		(24,344	)
Long-term liability balance as of September 30, 2025	$	348,984

During the three months ended September 30, 2025 and 2024, the Company recognized $8.7 million and $12.2 million, respectively, of interest expense in connection with the revenue interest financing liability. During the nine months ended September 30, 2025 and 2024, the Company recognized $30.1 million and $36.6 million, respectively, of interest expense in connection with the revenue interest financing liability.

F-14

The Company will record liabilities associated with achievement of the sales milestone when such contingent event occurs. To determine the accretion of the liability related to the Revenue Interest Financing Agreement, the Company is required to estimate the total amount of future royalty payments and estimated timing of such payments based on the Company’s revenue projections. As royalty payments are made, the balance of the debt obligation will be effectively repaid. Based on the Company’s periodic review, the exact timing of repayment is likely to be different in each reporting period as compared to those estimated in the Company’s initial revenue projections. A significant increase or decrease in actual net sales of vonoprazan compared to the Company’s revenue projections could impact the interest expense associated with the revenue interest financing liability. Also, the Company’s total obligation can vary depending on default events and achievement of the sales milestone.

7. Stockholders’ Equity

Common Stock

Underwritten Public Offerings

In August 2024, the Company sold 8,695,652 shares of common stock at a price of $11.50 per share and pre-funded warrants to purchase 2,608,922 shares of common stock at a price of $11.499 per pre-funded warrant for total gross proceeds of $130.0 million. The net purchase price after deducting the underwriting discounts and commissions and other offering expenses, was $10.77 per share, which generated net proceeds of $121.8 million. Certain affiliates of Frazier Life Sciences IX, L.P., or collectively, Frazier, a significant stockholder and Dr. James Topper, who currently serves on the Company's Board of Directors, share voting and investment power of the securities held by Frazier. Frazier participated in the offering by purchasing pre-funded warrants on the same terms as all other investors at a purchase price of $11.499, which represents the per share public offering price for the common stock less the $0.001 per share exercise price for each pre-funded warrant. Each pre-funded warrant became exercisable upon issuance and will not expire until exercised in full. The pre-funded warrants may not be exercised if the aggregate number of ordinary shares beneficially owned by the holders thereof immediately following such exercise would exceed a specified beneficial ownership limitation.

The pre-funded warrants were classified as a component of equity in the Company's balance sheets as they are freestanding financial instruments that are immediately exercisable, do not embody an obligation for the Company to repurchase its own shares and permit the holders to receive a fixed number of shares of common stock upon exercise. The Company valued the pre-funded warrants at issuance, concluding that their sales price approximated their fair value, and allocated net proceeds from the sale proportionately to the common stock and pre-funded warrants, of which $28.2 million was allocated to the pre-funded warrants and recorded as a component of additional paid-in capital. As of September 30, 2025, none of the pre-funded warrants have been exercised.

ATM Offerings

In November 2020, the Company entered into an Open Market Sale AgreementSM, or the Sales Agreement, with Jefferies LLC, or the Sales Agent, under which the Company may, from time to time, sell shares of common stock having an aggregate offering price of up to an amount registered under an effective registration statement through the Sales Agent.

In November 2023, the Company filed a shelf registration statement on Form S-3 which was declared effective by the SEC on November 17, 2023, which included an at-the-market prospectus pursuant to which the Company may, from time to time, sell up to an aggregate of $150 million of the Company's common stock through the Sales Agent, or the 2023 ATM Offering. The Company is not obligated to, and cannot provide any assurances that the Company will, make any sales of the shares under the Sales Agreement. The Sales Agreement may be terminated by the Sales Agent or the Company at any time. No shares were sold during the three and nine months ended September 30, 2025 and 2024. As of September 30, 2025, all of the available $150 million under the 2023 ATM Offering remains available.

F-15

Common Stock Reserves

Common stock reserved for future issuance consists of the following:


	September 30, 2025
Common stock warrants including pre-funded warrants		2,700,150
Stock options, performance stock units and restricted stock units outstanding		12,240,909
Shares available for issuance under the 2019 Incentive Plan		1,924,014
Shares available for issuance under the ESPP Plan		1,357,508
Shares available for issuance under the Inducement Plan		428,092
Balance at September 30, 2025		18,650,673

Preferred Stock

The Company is authorized to issue up to 40 million shares of preferred stock. As of September 30, 2025 and December 31, 2024, there were no shares of preferred stock issued or outstanding.

Equity Incentive Plan

The Company’s 2019 Equity Incentive Plan, or the Prior Incentive Plan, provided for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, and other stock awards to eligible recipients, including employees, directors or consultants of the Company. The Company had 2,231,739 shares of common stock authorized for issuance under the Prior Incentive Plan, of which, 1,400,528 stock options and 16,260 restricted stock awards were granted in 2019. As a result of the adoption of the 2019 Incentive Award Plan, or the 2019 Plan, in October 2019, no further awards may be available for issuance under the Prior Incentive Plan.

2019 Incentive Award Plan

In October 2019, the Board of Directors adopted, and the Company’s stockholders approved, the 2019 Plan, which became effective in connection with the IPO. Under the 2019 Plan, the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units, or RSUs, performance stock units, or PSUs, and other awards to individuals who are then employees, officers, non-employee directors or consultants of the Company or its subsidiaries. The number of shares initially available for issuance will be increased by (i) the number of shares subject to stock options or similar awards granted under the Prior Incentive Plan that expire or otherwise terminate without having been exercised in full after the effective date of the 2019 Plan and unvested shares issued pursuant to awards granted under the Prior Incentive Plan that are forfeited to or repurchased by the Company after the effective date of the 2019 Plan, with the maximum number of shares to be added to the 2019 Plan pursuant to clause (i) above or equal to 1,416,788 shares, and (ii) an annual increase on January 1 of each calendar year beginning in 2020 and ending in 2029, equal to the lesser of (a) 5% of the shares of common stock outstanding on the final day of the immediately preceding calendar year and (b) such smaller number of shares as determined by the Board of Directors.

As of September 30, 2025, 1,924,014 shares remain available for issuance under the 2019 Plan, which reflects 5,406,581 stock options, RSUs and PSUs granted, and 2,325,794 of awards cancelled or forfeited, during the nine months ended September 30, 2025 as well as an annual increase of 3,425,913 shares authorized on January 1, 2025.

2025 Employment Inducement Incentive Award Plan

On March 30, 2025, the Board of Directors adopted the 2025 Employment Inducement Incentive Award Plan, or the Inducement Plan, and reserved 2,500,000 shares of the Company’s common stock for issuance pursuant to equity awards granted under the Inducement Plan to individuals not previously employees or non-employee directors of the Company (or following such individuals’ bona fide period of non-employment with the Company) as an inducement to join the Company. The Inducement Plan provides for the grant of equity-based awards, including nonstatutory stock options, RSUs, restricted stock, stock appreciation rights, performance shares and PSUs, and its terms are substantially similar to the Company’s 2019 Plan, but with such other terms and conditions intended to comply with the Nasdaq inducement award exception or to comply with the Nasdaq acquisition and merger exception. During the nine months ended September 30, 2025, the Company granted 2,071,908 stock options, RSUs and PSUs under the Inducement Plan. As of September 30, 2025, 428,092 shares remain available for issuance.

F-16

Performance-Based Units

In 2025, the Board of Directors approved the grant of PSUs, whereby vesting depends on certain revenue performance milestones each year and over the next three years and stock price hurdle PSUs granted pursuant to the Inducement Plan. The Company estimates the likelihood of achievement of performance milestones for all PSU awards at the end of each reporting period. To the extent those awards or portions thereof are considered probable of being achieved, such awards or portions thereof are expensed over the performance period.

The following table summarizes PSU activity during the nine months ended September 30, 2025:


	Number of Stock Units			Weighted- Average Grant Date Fair Value Per Share
Unvested balance at January 1, 2025		—		$	—
Granted		1,178,200			5.57
Vested		(90,000	)		5.01
Forfeited		(420,425	)		5.76
Unvested balance at September 30, 2025		667,775		$	5.52

Stock-based compensation expense is recorded based on the market price of the Company's common stock on the grant date and is recognized if and when the achievement of such performance milestones are determined to be probable by the Company. During the three months ended September 30, 2025, a revenue performance milestone was considered probable, and the Company recognized stock-based compensation expense related to the probable vesting of PSUs of approximately $1.5 million. In addition, a stock price hurdle milestone was achieved and the Company recorded $1.0 million of stock-based compensation expense upon vesting of the stock price hurdle PSUs. The fair value of the PSUs that vested upon achievement of this milestone was $0.5 million at the vesting date. As a result, the Company recognized a total of $2.5 million of stock-based compensation expense during the three and nine months ended September 30, 2025. As of September 30, 2025, there was approximately $2.2 million of related unrecognized stock-based compensation expense related to PSUs.

Restricted Stock Units

The following table summarizes RSU activity during the nine months ended September 30, 2025:


	Number of Stock Units			Weighted- Average Grant Date Fair Value Per Share
Unvested balance at January 1, 2025		2,382,660		$	10.32
Granted		1,744,016			5.62
Vested		(1,316,012	)		11.35
Forfeited		(689,921	)		9.00
Unvested balance at September 30, 2025		2,120,743		$	6.25

As of September 30, 2025, the Company had $11.4 million of unrecognized stock-based compensation expense related to RSUs, which is expected to be recognized over a weighted-average period of 1.6 years. The total fair value of RSUs vested during the nine months ended September 30, 2025, was approximately $14.9 million.

F-17

Employee Stock Purchase Plan

In October 2019, the Board of Directors adopted, and the Company’s stockholders approved, the Employee Stock Purchase Plan, or the ESPP, which became effective in connection with the IPO. The ESPP permits participants to purchase common stock through payroll deductions of up to 20% of their eligible compensation, which includes a participant’s gross base compensation for services to the Company, including overtime payments and excluding sales commissions, incentive compensation, bonuses, expense reimbursements, fringe benefits and other special payments. A total of 270,000 shares of common stock were initially reserved for issuance under the ESPP. In addition, the number of shares available for issuance under the ESPP will be annually increased on January 1 of each calendar year beginning in 2020 and ending in 2029, by an amount equal to the lesser of: (i) 1% of the shares outstanding on the final day of the immediately preceding calendar year and (ii) such smaller number of shares as is determined by the Board of Directors. As of September 30, 2025, 1,357,508 shares of common stock remain available for issuance under the ESPP, which includes the 505,293 shares sold to employees during the nine months ended September 30, 2025 as well as an annual increase of 685,183 shares authorized on January 1, 2025.

The ESPP is considered a compensatory plan, and for the three and nine months ended September 30, 2025, the Company recorded related stock-based compensation of $0.1 million and $0.9 million, respectively, compared to $0.1 million and $1.3 million, respectively, for the same periods in 2024. The weighted-average assumptions used to estimate the fair value of ESPP awards using the Black-Scholes option valuation model were as follows:


	Nine Months Ended September 30,
	2025	2024
Assumptions:
Expected term (in years)	0.49	0.49
Expected volatility	112.83%	105.23%
Risk free interest rate	4.29%	5.19%
Dividend yield	—	—

The estimated weighted-average fair value of ESPP awards for the nine months ended September 30, 2025 and 2024, was $3.62 and $4.03, respectively. As of September 30, 2025, the total unrecognized compensation expense related to the ESPP was $0.7 million, which is expected to be recognized over a weighted-average period of approximately 0.3 years.

401(k) Plan

During 2020, the Company established a 401(k) savings plan. The Company’s contributions to the plan are discretionary. During the three and nine months ended September 30, 2025, the Company incurred $1.2 million and $4.3 million, respectively, of expense related to estimated employer contribution liabilities, which was based on a 75% match of employees’ contributions during the periods, compared to $1.2 million and $4.2 million, respectively, for the same periods in 2024. During the nine months ended September 30, 2025 and 2024, the Board of Directors approved employer matching contributions settled by contributing 616,377 and 383,589, respectively, shares of common stock.

Stock Options

The fair value of each employee and non-employee stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. The Company, prior to the IPO on October 29, 2019, was a private company and lacked company-specific historical and implied volatility information. Therefore, the Company estimated its expected volatility based on the historical volatility of a publicly traded set of peer companies. Due to the lack of historical exercise history, the expected term of the Company’s stock options for employees was determined utilizing the “simplified” method for awards. The expected term of stock options granted to non-employees was equal to the contractual term of the option award. The risk-free interest rate was determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield was zero based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future.

F-18

A summary of the Company’s stock option activity and related information is as follows:


	Options Outstanding			Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term		Aggregate Intrinsic Value (in thousands)
Balance at January 1, 2025		6,157,532		$	10.29		7.59	$	2,133
Options granted		4,556,273			5.15
Options exercised		(45,966	)		8.11
Options cancelled		(1,215,448	)		7.41
Balance at September 30, 2025		9,452,391		$	8.20		6.69	$	41,354
Options exercisable as of September 30, 2025		4,496,492		$	10.71		3.90	$	11,984
Vested and expected to vest as of September 30, 2025		9,452,391		$	8.20		6.69	$	41,354

The estimated weighted-average fair value of employee and nonemployee director stock options granted for the nine months ended September 30, 2025 and 2024 was $3.80 and $5.55, respectively. As of September 30, 2025, the Company had $18.8 million of unrecognized stock-based compensation expense related to stock options, which is expected to be recognized over a weighted-average period of 3.0 years.

The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company's common stock for those stock options that had exercise prices lower than the fair value of the Company's common stock at September 30, 2025. The total intrinsic value of stock options exercised for the nine months ended September 30, 2025 was approximately $0.1 million.

The weighted-average assumptions used to estimate the fair value of stock options using the Black-Scholes option valuation model were as follows:


	Nine Months Ended September 30,
	2025	2024
Assumptions:
Expected term (in years)	6.07	6.04
Expected volatility	84.59%	74.67%
Risk free interest rate	4.07%	4.14%
Dividend yield	—	—

Stock-Based Compensation Expense

Stock-based compensation expense recognized for all equity awards has been reported in the condensed statements of operations and comprehensive loss as follows (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2025		2024		2025		2024
Research and development expense	$	2,063	$	1,296	$	5,043	$	3,876
Selling, general and administrative expense		7,234		4,339		18,066		13,484
Total	$	9,297	$	5,635	$	23,109	$	17,360

F-19

8. Revenue Recognition

To date, our only source of revenue has been from the U.S. sales of VOQUEZNA products, which the Company began selling during the fourth quarter of 2023. The Company records its best estimate of chargebacks, sales discounts and other reserves to which customers are likely expected to be entitled to as contra accounts receivable charges, and within accrued expenses if payable to a third-party or related to product returns on the condensed balance sheets. During the nine months ended September 30, 2025 and 2024, the Company recognized $117.5 million and $25.6 million, respectively, of net product revenues related to sales of VOQUEZNA, VOQUEZNA DUAL PAK and VOQUEZNA TRIPLE PAK.

The following table provides a summary of the Company's revenue allowances and related accruals for the nine months ended September 30, 2025, which have been deducting in arriving at product revenues, net (in thousands):


	Customer Credits, Discounts and Allowance			Rebates, Returns and Co-Pay Assistance
	(contra accounts receivable)			(accrued expenses)			Total
Balance as of January 1, 2025	$	5,659		$	29,987		$	35,646
Accruals		44,000			104,384			148,384
Utilizations		(40,306	)		(90,273	)		(130,579	)
Balance as of September 30, 2025	$	9,353		$	44,098		$	53,451

9. Segment Information

The Company's chief operating decision maker, or CODM, the Chief Executive Officer, manages the Company’s business activities as a single reportable segment. The segment derives its current revenues from the sale of VOQUEZNA products. Accordingly, the CODM uses net loss to measure segment profit or loss, allocate resources and assess performance. Further, the CODM reviews and utilizes functional expenses (research and development, general and administrative, sales and marketing and stock-based compensation) to manage the Company’s operations. Other segment items included in net loss are interest income, interest expense and other expense, which are reflected in the condensed statements of operations and comprehensive loss. The measure of segment assets is reported on the condensed balance sheets as total assets.

The following table presents selected financial information with respect to the Company’s single operating segment for the nine months ended September 30, 2025 and 2024 (in thousands):


	Nine Months Ended September 30,
	2025			2024
Product revenue, net	$	117,526		$	25,588
Less:
Cost of revenue		14,951			4,158
Research and development		20,244			21,623
General and administrative		26,856			21,159
Sales and marketing		186,424			179,338
Stock-based compensation		23,109			17,360
Interest income		(5,840	)		(11,648	)
Interest expense		51,696			53,416
Other expense, net		185			57
Segment net loss	$	(200,099	)	$	(259,875	)

F-20

10. Restructuring

In May 2025, the Company implemented a cost reduction and organizational restructuring plan to reduce cash burn and focus resources on commercial execution. In connection with the restructuring, the Company's workforce was reduced by 26 employees, or approximately 6%, including certain leadership changes all designed to right-size the organization. During the nine months ended September 30, 2025, total restructuring charges incurred were $9.2 million consisting of one-time termination benefits to affected employees for severance, non-cash stock-based compensation costs, healthcare benefits and outplacement assistance. The costs are included in research and development and selling, general, and administrative expenses on the Company’s condensed consolidated statement of operations and comprehensive loss.

The following table summarizes activity related to the restructuring accrual during the nine months ended September 30, 2025 (in thousands):


	Total
Restructuring expenses incurred	$	9,214
Cash paid		(3,242	)
Non-cash expenses		(4,597	)
Balance as of September 30, 2025	$	1,375

11. Subsequent Event

Effective October 6, 2025, the Company announced the appointment of Sanjeev Narula as the new Chief Financial and Business Officer. Mr. Narula will also serve as principal financial officer of the Company and entered into an employment agreement with the Company, setting forth the terms of his employment which is filed as an exhibit to this Quarterly Report on Form 10-Q.

F-21

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

You should read the following discussion and analysis of our financial condition and results of operations in conjunction with the unaudited interim condensed financial statements and notes thereto included in this Quarterly Report on Form 10-Q and with our audited financial statements and notes thereto for the year ended December 31, 2024 and the related Management’s Discussion and Analysis of Financial Condition and Results of Operations, both of which are contained in our Annual Report on Form 10-K for the year ended December 31, 2024, or the 2024 Form 10-K.

Forward Looking Statements

The following discussion and other parts of this quarterly report contain forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. All statements other than statements of historical facts contained in this quarterly report, including statements regarding our future results of operations and financial position, business strategy, commercialization plans and costs, research and development plans and costs, pricing and reimbursement, the potential to develop future product candidates, the timing and likelihood of success of the plans and objectives of management for current and future operations, and future results of anticipated commercialization, product development and other efforts, are forward-looking statements. These statements are often identified by the use of words such as “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “should,” “estimate,” or “continue,” and similar expressions or variations. The forward-looking statements in this quarterly report are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, operating results, business strategy, short-term and long-term business operations and objectives. These forward-looking statements speak only as of the date of this quarterly report and are subject to a number of risks, uncertainties and assumptions, including those described in the Part II, Item 1A under the heading “Risk Factors" of our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Overview

We are a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Our approved products, VOQUEZNA®, VOQUEZNA® TRIPLE PAK® and VOQUEZNA® DUAL PAK®, contain vonoprazan, an oral small molecule potassium-competitive acid blocker, or PCAB. PCABs are a novel class of medicines that block acid secretion in the stomach. Vonoprazan is the first gastric anti-secretory agent from a novel class approved in the United States, Europe, or Canada in over 30 years, and has shown rapid, potent, and durable anti-secretory effects. Vonoprazan has also demonstrated clinical benefits over the current standard of care as a single agent in the treatment of erosive gastroesophageal reflux disease, or Erosive GERD, and in combination with antibiotics for the treatment of Helicobacter pylori, or H. pylori, infection. Takeda Pharmaceutical Company Limited, or Takeda, developed vonoprazan and has received marketing approval in numerous countries in Asia and Latin America as well as Russia. Vonoprazan generated peak net sales for Takeda of approximately $850 million and continues to achieve volume growth during its tenth full year on the market since its approval in Japan in 2014. In May 2019, we in-licensed the U.S., European, and Canadian rights to vonoprazan from Takeda.

In May 2022, the U.S. Food and Drug Administration, or FDA, approved the NDAs for vonoprazan triple therapy, under the brand name VOQUEZNA TRIPLE PAK, and vonoprazan dual therapy, under the brand name VOQUEZNA DUAL PAK. Subsequently, on November 1, 2023, the FDA approved vonoprazan, under the brand name VOQUEZNA, as a treatment for adults for the healing of all grades of Erosive GERD, maintenance of healing of all grades of Erosive GERD, and relief of heartburn associated with Erosive GERD, as well as in combination with amoxicillin, with or without clarithromycin, for the treatment of H. pylori infection in adults. We initiated commercial launch for VOQUEZNA for both the Erosive GERD and H. pylori indications, and VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK for treatment of H. pylori infection in the fourth quarter of 2023. In September 2023, we submitted an NDA seeking approval of vonoprazan as a once-daily treatment for heartburn symptoms associated with Non-Erosive GERD in adults. On July 17, 2024, the FDA approved VOQUEZNA 10 mg tablets for the relief of heartburn associated with Non-Erosive GERD, the largest category of GERD.

We are independently commercializing VOQUEZNA, VOQUEZNA TRIPLE PAK, and VOQUEZNA DUAL PAK in the United States. Our commercial launch for VOQUEZNA continues to build momentum and launch data shows strong physician and patient demand. As of October 17, 2025, over 790,000 prescriptions for VOQUEZNA tablets, VOQUEZNA Triple Pak, and VOQUEZNA Dual Pak have been filled since launch written by more than 34,100 prescribers. We continue to maintain broad commercial coverage for VOQUEZNA with over 120 million, or over 80%, of total U.S. commercial lives with access to VOQUEZNA tablets.

We continue to evaluate potential for commercial partnerships for vonoprazan in Europe and Canada as well as potential development of vonoprazan into other indications, dosing regimens and alternative formulations and packaging. We also plan to evaluate the in-license or acquisition of additional clinical or commercial stage product candidates for the treatment of GI diseases in a capital efficient manner. We initiated our Phase 2 clinical trial of vonoprazan in eosinophilic esophagitis (EoE) trial during the fourth quarter of 2025.

In May 2021, the FDA granted qualified infectious disease product, or QIDP, designations for VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK and we thereby received an extension of five years of new chemical entity, or NCE, exclusivity based on the vonoprazan component in the applicable NDAs. In December 2024, we submitted a citizen petition requesting that FDA update the Orange Book listings to reflect the same ten-year period of NCE exclusivity for VOQUEZNA as reflected on the VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK Orange Book listings. On June 16, 2025, we announced that the FDA has updated the Orange Book listing for VOQUEZNA tablets to reflect the full ten-year period of NCE exclusivity now extended through May 3, 2032.

We had previously been informed by Sandoz that there could be a disruption in the supply of clarithromycin tablets, a component of the VOQUEZNA TRIPLE PAK. Given more recent communications, however, we do not currently anticipate any near-term supply issues. We plan to continue to actively monitor the situation to determine if a supply disruption may still arise in the future. The VOQUEZNA TRIPLE PAK represents approximately 1% of our total revenue. While we have not experienced any commercial disruption to date, any disruption for such supply would result in our inability to continue to commercialize the VOQUEZNA TRIPLE PAK. The VOQUEZNA bottles and the VOQUEZNA DUAL PAKs are not impacted, as they do not include clarithromycin.

We commenced our operations in 2018 and have devoted substantially all of our resources to date to organizing and staffing our company, business planning, raising capital, in-licensing vonoprazan, meeting with regulatory authorities, managing our clinical trials of vonoprazan, preparing for commercialization of our products containing vonoprazan, commercially launching our approved products in the U.S., and providing other selling, general and administrative support for our operations. Our operations to date have been funded primarily through commercial bank debt, our revenue interest financing debt and various equity offerings, including our at-the-market offerings. From inception through September 30, 2025, we sold 34,737,032 shares of our common stock and 2,608,922 pre-funded warrants, generating net proceeds of approximately $543.3 million, after deducting underwriting discounts, commissions and offering costs. As of September 30, 2025, we had cash and cash equivalents of $135.2 million. Based on our current operating plan, we believe that our existing cash and cash equivalents together with anticipated product revenues, are sufficient to fund operations for at least the next twelve months.

Since inception, we have incurred significant operating losses. Our net losses were $200.1 million and $259.9 million for the nine months ended September 30, 2025 and 2024, respectively. As of September 30, 2025, we had an accumulated deficit of $1.5 billion. Despite our plans and expectations, we could continue to incur operating losses for the foreseeable future. If we do not achieve our goals, it could be several years, if ever, before our current products or potential future product candidates, if successfully developed and approved, generate significant revenues to offset these operating losses. As a result, we are uncertain if we will achieve profitability on our current expected timeline, if at all, and, if so, whether we will be able to sustain it. The net losses we incur may fluctuate significantly from quarter to quarter and year to year.

While we have generated revenue to date, until such time as we can generate significant revenue from sales of our approved products containing vonoprazan, we also expect to finance our cash needs through equity offerings, additional debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when and if needed on favorable terms or at all, and this risk could be exacerbated by the impact of ongoing conflicts throughout the world and global economic conditions. Our failure to raise capital or enter into such other arrangements when needed would have a negative impact on our financial condition and could force us to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.

Restructuring

In May 2025, we implemented a cost reduction and organizational restructuring plan to reduce cash burn and focus resources on commercial execution. In connection with the restructuring, our workforce was reduced by 26 employees, or approximately 6%, including certain leadership changes all designed to right-size the organization. During the nine months ended September 30, 2025, total restructuring charges incurred were $9.2 million consisting of one-time termination benefits to affected employees for severance, non-cash stock-based compensation costs, healthcare benefits and outplacement assistance. As of September 30, 2025, approximately $1.4 million of restructuring related accruals remain on the condensed balance sheet.

License Agreement with Takeda

On May 7, 2019, we and Takeda entered into an exclusive license, or the Takeda License, pursuant to which we in-licensed the U.S., European, and Canadian rights to vonoprazan fumarate. During the term of the Takeda License, we and our affiliates are not permitted to commercialize any pharmaceutical product, other than vonoprazan, that treats acid-related disorders, except for certain generic and OTC competing products in specified circumstances. We are responsible at our cost for the development, manufacture and commercialization of vonoprazan products. We are required to use commercially reasonable efforts to develop and commercialize the vonoprazan products in our licensed territory.

Under the Takeda License, Takeda has the sole right and authority, with our input, to prepare, file, prosecute, and maintain all Takeda and joint patents on a worldwide basis at its own cost. We are responsible, at our cost, for preparing, filing, prosecuting, and maintaining patents on inventions made solely by us in connection with vonoprazan, subject to input from Takeda.

We paid Takeda upfront consideration consisting of a cash fee of $25 million, 1,084,000 shares of our common stock, a warrant to purchase 7,588,000 shares of our common stock at an exercise price of $0.00004613 per share, or the Takeda Warrant, and issued Takeda a right to receive an additional common stock warrant, or the Takeda Warrant Right, if Takeda’s fully-diluted ownership of the Company represented less than a certain specified percentage of the fully-diluted capitalization, including shares issuable upon conversion of then outstanding convertible promissory notes, calculated immediately prior to the closing of our IPO. The Takeda Warrant Right expired without effect since no fair value had been allocated to it upon completion of our IPO, and no additional warrant was issued. We agreed to make milestone payments to Takeda upon achieving certain tiered aggregate annual net sales of licensed products in the United States, Europe and Canada up to a total maximum milestone amount of $250 million. We also agreed to make tiered royalty payments at percentages averaging in the low double digits on net sales of licensed products, subject to specified offsets and reductions. Royalties will be payable, on a product-by-product and country-by-country basis from the first commercial sale of such product in such country, until the latest of expiration of the licensed patents covering the applicable product, expiration of regulatory exclusivity in such country, or 15 years following first commercial sale in such country. We currently pay royalties to Takeda on sales of VOQUEZNA tablets, VOQUEZNA DUAL PAK and VOQUEZNA TRIPLE PAK in the U.S.

Components of Results of Operations

Revenue

We began to recognize revenue from product sales, net of rebates, chargebacks, discounts, and other adjustments, in November 2023 in conjunction with the commercial launch of VOQUEZNA, VOQUEZNA TRIPLE PAK, and VOQUEZNA DUAL PAK in the United States.

Cost of Revenue

Cost of revenue includes the cost of producing and distributing inventories that are related to product sales. This also includes royalties payable to Takeda, pursuant to the Takeda License Agreement (Refer to Note 3 for further details). In addition, shipping and handling costs for product sales are recorded as incurred. Cost of revenue also includes costs related to excess or obsolete inventory adjustment charges.

Operating Expenses

Research and Development

To date, our research and development expenses have related to the development and regulatory approvals of vonoprazan. Research and development expenses are recognized as incurred and payments made prior to the receipt of goods or services to be

used in research and development are capitalized until the goods or services are received. We do not track total research and development expenses by indication.

Research and development expenses include:

•

Clinical development expenses: external research and development expenses incurred under agreements with CROs, regulatory costs, and consultants to conduct and support our clinical trials of vonoprazan;

•

Personnel related expenses: salaries, payroll taxes, and employee benefits;

•

Chemistry manufacturing and controls, or CMC, expenses: costs related to the manufacturing of vonoprazan for our clinical trials;

•

Consulting, professional and other costs: external costs related to consulting and professional services and other research costs incurred; and

•

Stock-based compensation expenses: stock-based compensation expense recognized for those individuals involved in research and development efforts.

The following table summarizes our research and development expenses for the three and nine months ended September 30, 2025 and 2024 (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2025		2024		2025		2024
Clinical development and regulatory	$	1,410	$	2,640	$	7,405	$	8,757
Personnel related

Phathom Pharmaceuticals, Inc. 10-Q